Quest Diagnostics has signed up to offer a blood test that can help diagnose Alzheimer’s disease, following its FDA clearance earlier this year. | The Lumipulse G blood test measures the ratio between ...

Quest will offer the first FDA-approved blood test to help detect Alzheimer’s-related amyloid pathology in patients with ...

Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, including advanced diagnostics for brain health, today announced it plans to offer laboratory testing based on the ...

Despite concerns raised by clinicians and ethicists, direct-to-consumer testing for Alzheimer’s disease biomarkers is here, ...

Quest Diagnostics to offer US FDA-approved Fujirebio blood test for Alzheimer's disease: Secaucus, New Jersey Friday, July 11, 2025, 14:00 Hrs [IST] Quest Diagnostics, a leader in ...

Indiana University School of Medicine researcher Jeff Dage’s years of research into biomarkers helped lead to a first-of-its-kind blood test to diagnose Alzheimer’s disease.

The FDA has approved the first blood test for Alzheimer's disease based on a blood test – from Fujirebio – in a step forward for early diagnosis. The test, dubbed the Lumipulse G pTau217/ß ...

Lumipulse G is not the only Alzheimer’s blood test available, but it’s the first to be introduced since the FDA increased oversight on lab tests. FDA approved Lumipulse G only for patients ...

H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G sTREM2 assay for the fully automated LUMIPULSE® G immunoassay analyzers.